Jane Street Group LLC Acquires 1,929 Shares of Zynex, Inc. (NASDAQ:ZYXI)

Jane Street Group LLC raised its holdings in Zynex, Inc. (NASDAQ:ZYXI) by 8.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,530 shares of the company’s stock after purchasing an additional 1,929 shares during the period. Jane Street Group LLC owned approximately 0.07% of Zynex worth $192,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ZYXI. Hotchkis & Wiley Capital Management LLC raised its stake in Zynex by 24.7% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 746,380 shares of the company’s stock valued at $6,090,000 after purchasing an additional 147,770 shares in the last quarter. Millennium Management LLC raised its position in shares of Zynex by 66.5% in the 2nd quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock valued at $2,769,000 after buying an additional 118,615 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Zynex by 68.7% during the 2nd quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock worth $1,769,000 after acquiring an additional 77,300 shares during the period. GSA Capital Partners LLP boosted its position in shares of Zynex by 72.7% during the 3rd quarter. GSA Capital Partners LLP now owns 79,930 shares of the company’s stock worth $652,000 after acquiring an additional 33,649 shares in the last quarter. Finally, Janney Montgomery Scott LLC increased its stake in Zynex by 22.3% in the third quarter. Janney Montgomery Scott LLC now owns 144,439 shares of the company’s stock valued at $1,179,000 after acquiring an additional 26,368 shares during the last quarter. Institutional investors and hedge funds own 29.68% of the company’s stock.

Zynex Trading Down 2.6 %

Shares of ZYXI stock opened at $7.83 on Monday. Zynex, Inc. has a twelve month low of $7.15 and a twelve month high of $13.77. The stock’s fifty day simple moving average is $8.22 and its 200 day simple moving average is $8.33. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. The firm has a market capitalization of $249.35 million, a P/E ratio of 52.20 and a beta of 0.53.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings results on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.01. The company had revenue of $49.97 million for the quarter, compared to analysts’ expectations of $50.83 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The business’s quarterly revenue was up .1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.10 earnings per share. As a group, sell-side analysts predict that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Insider Activity

In related news, CFO Daniel J. Moorhead sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $7.88, for a total value of $78,800.00. Following the sale, the chief financial officer now directly owns 26,299 shares in the company, valued at $207,236.12. This represents a 27.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 44,000 shares of company stock valued at $368,040. Insiders own 52.13% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ZYXI shares. HC Wainwright reissued a “buy” rating and set a $17.00 price target on shares of Zynex in a report on Friday, December 6th. Royal Bank of Canada reduced their price target on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th.

Zynex Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.